Skip to content
2000
Volume 16, Issue 5
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

Fanconi anemia (FA) is an autosomal recessive, multisystem DNA repair disorder with prominent defects in the hematopoietic stem cell maintenance that result in the progressive attrition and failure in the early school age. Allogeneic stem cell transplantation has proved curative for patients with suitable donors. This, along with the characteristic survival advantage of phenotypically normal over non-corrected FA stem cells underscores the compelling rationale for stem cell gene therapy in the FA. While integrating lentiviral vectors (LV) have become the preferred platform for genetic correction in several hematologic and immunodeficiency disorders, the residual oncogenic potential by these vectors raises concerns in the FA stem cells about insertional mutagenic genetic lesions. On this backdrop, investigators are developing a new generation of non-integrating viral vectors capable of nuclear persistence through serial mitotic cycles and stable under selection to offset the comparatively lower transduction rates. Here, we review the competing approaches to develop such non-integrating lentiviral (NILV) episome vectors that faithfully replicate in the stem cells.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/1566523217666170113165407
2016-10-01
2025-07-07
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/1566523217666170113165407
Loading

  • Article Type:
    Research Article
Keyword(s): Fanconi anemia; Gene therapy; Hematopoietic stem/progenitor cells; S/MAR; Viral vectors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test